Skip to main content
. 2016 Jan 25;7(6):7307–7317. doi: 10.18632/oncotarget.7007

Figure 1. IL-32θ inhibits colon cancer tumorigenicity in vitro.

Figure 1

(A) The migration abilities of HT29 and HT29-IL-32θ cells were analyzed by wound healing assays. Wounds were made using pipette tips and cell motility was observed after 48 h. (B) The invasive capacities of HT29 and HT29-IL-32θ cells were analyzed using matrigel invasion assays. Phase-contrast microscopy images are shown. Values are presented as the mean ± S.D. (N = 3). (C) DNA content of HT29 and HT29-IL-32θ cells as determined by flow cytometry. *p < 0.05 and **p < 0.005.